Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900402 | 1.00 | CES2 (0.61) | CES2ALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL26279698 | 1.00 | CES2 (0.61) | CES2ALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL16329739 | 1.00 | CES2 (0.61) | CES2ALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL13971269 | 1.00 | CES2 (0.61) | CES2ALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL8383900 | 0.95 | — | — | |
| SCHEMBL17174610 | 0.91 | CES2 (0.69) | CES2ALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL6259731 | 0.91 | CES2 (0.76) | CES2ALDH1A1TSHRTHRBMEN1 | |
| SCHEMBL22198415 | 0.89 | CES2 (0.58) | CES2ALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL20932195 | 0.89 | CES2 (0.58) | CES2ALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL26279694 | 0.89 | CES2 (0.58) | CES2ALDH1A1TSHRTDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216166-B2 | Anti-microbial photodynamic therapy | Biolitec Pharma Marketing, Ltd (MY) | 2015-12-22 | — | — | US | disclosed |
| US-20090326434-A1 | Anti-Microbial Photodynamic Therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326434-A1 | Anti-Microbial Photodynamic Therapy | CD47, EPOR, ENPEP | CES2 2224/4885ALDH1A1 1139/4885TSHR 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.